Abstract
Background: Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed. Methods: We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load + T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV. Conclusions: An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.
| Original language | English |
|---|---|
| Pages (from-to) | 993-1002 |
| Number of pages | 10 |
| Journal | Antiviral Therapy |
| Volume | 15 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2010 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Cite this
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. / Ghosn, Jade; Carosi, Giampiero; Moreno, Santiago; Pokrovsky, Vadim; Lazzarin, Adriano; Pialoux, Gilles; Sanz-Moreno, Jose; Balogh, Agnes; Vandeloise, Eric; Biguenet, Sophie; Leleu, Ghislaine; Delfraissy, Jean Francois.
In: Antiviral Therapy, Vol. 15, No. 7, 2010, p. 993-1002.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
AU - Ghosn, Jade
AU - Carosi, Giampiero
AU - Moreno, Santiago
AU - Pokrovsky, Vadim
AU - Lazzarin, Adriano
AU - Pialoux, Gilles
AU - Sanz-Moreno, Jose
AU - Balogh, Agnes
AU - Vandeloise, Eric
AU - Biguenet, Sophie
AU - Leleu, Ghislaine
AU - Delfraissy, Jean Francois
PY - 2010
Y1 - 2010
N2 - Background: Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed. Methods: We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load + T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV. Conclusions: An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.
AB - Background: Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed. Methods: We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load + T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV. Conclusions: An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.
UR - http://www.scopus.com/inward/record.url?scp=78651113527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651113527&partnerID=8YFLogxK
U2 - 10.3851/IMP1666
DO - 10.3851/IMP1666
M3 - Article
C2 - 21041914
AN - SCOPUS:78651113527
VL - 15
SP - 993
EP - 1002
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - 7
ER -